A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.
List view / Grid view
type 1 diabetes
Filter the results
A key process in β-cell regeneration has been discovered by researchers who say this could lead to improved treatments for diabetes.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
Researchers suggest that identifying new treatments for autoimmune diseases requires studying the immune system AND target tissues together.
Researchers engineered the Disque Platform, a high-fidelity culture system, to enable them to screen drugs able to promote β cell proliferation.
Researchers have developed a novel insulin molecule that responds to glucose levels in the blood sugar of rats, which they say could help patients with type 1 diabetes.
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
Scientists denervated the pancreas using surgery or pharmacological agents to protect it from immune-mediated beta cell destruction, preventing the onset of type 1 diabetes.
A study has shown that SRI-37330 is successful at improving the characteristics of diabetes in human pancreatic islets and animal models.
The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
New research indicates COVID-19 could trigger the development of diabetes in healthy people, prompting experts to establish a registry for COVID-19 and diabetes data.
Researchers observed that deleting the IRE1-alpha gene caused beta cells to de-differentiate and then re-differentiate in mice, preventing immune system auto-activation.
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
Researchers have discovered that type 1 diabetes patients have low levels of growth differentiation factor 15 (GDF15) in their pancreatic β cells, unlocking a potential alternative to life-long type 1 diabetes disease management.